Back to Browse Journals » Journal of Inflammation Research » Volume 3

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Authors Slobodan M Jankovic

Published Date March 2010 Volume 2010:3 Pages 25—31

DOI http://dx.doi.org/10.2147/JIR.S9480

Published 16 March 2010

Slobodan M Jankovic

Pharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, Serbia

Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not characteristic, followed by partial or complete recovery. Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur throughout the life of a patient, with periods of partial or complete remission and clinical stability in between. Currently, there are several therapeutic options for MS with disease-modifying properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific receptors on surface of immune cells, changing the expression of several genes and leading to a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompatibility complex class II expression and reduction in inflammatory cells migration into the central nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% (1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 31% more patients relapse-free. In secondary-progressive disease annual rate of progression is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in  relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of immunological therapies for this debilitating disease.
Keywords: multiple sclerosis, interferon beta 1b, mechanism of action, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS

OncoTargets and Therapy 2013, 6:371-389

Published Date: 15 April 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Corneal topographic changes following trans-conjunctival 20 gauge sutureless vitrectomy (TC20V)

Abdel Alim Mohamed A, Abdrabbo M

Clinical Ophthalmology 2012, 6:565-569

Published Date: 24 April 2012

Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania

Mugoyela V, Minzi 0

Risk Management and Healthcare Policy 2011, 4:89-95

Published Date: 6 September 2011

Corneal abrasion

Scott Fraser

Clinical Ophthalmology 2010, 4:387-390

Published Date: 26 April 2010

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Joan Khoo, Christopher K Rayner, Karen L Jones, et al

Therapeutics and Clinical Risk Management 2009, 5:683-698

Published Date: 20 August 2009

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009

Methylnaltrexone in the treatment of opioid-induced constipation

Beverley Greenwood-Van Meerveld, Kelly M Standifer

Clinical and Experimental Gastroenterology 2008, 1:49-58

Published Date: 14 December 2008